Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;35(6):1213-8.
doi: 10.2337/dc11-2081. Epub 2012 Mar 23.

Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies

Collaborators, Affiliations

Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies

Liping Yu et al. Diabetes Care. 2012 Jun.

Abstract

Objective: We assessed diabetes risk associated with zinc transporter-8 antibodies (ZnT8A), islet cell antibodies (ICA), and HLA type and age in relatives of people with type 1 diabetes with the standard biochemical autoantibodies (BAA) to insulin (IAA), GAD65 (GAD65A), and/or insulinoma-associated protein 2 antigen (IA-2A).

Research design and methods: For this analysis, 2,256 relatives positive for at least one BAA, of whom 142 developed diabetes, were tested for ZnT8A, ICA, and HLA genotype followed by biannual oral glucose tolerance tests. ZnT8A were also tested in 911 randomly chosen antibody-negative relatives.

Results: ZnT8A were associated with the other BAA (548 of 2,256 [24.3%] BAA(+) vs. 8 of 911 [0.8%] BAA(-), P < 0.001) and BAA number (177 of 1,683 [10.5%] single-, 221 of 384 [57.6%] double-, and 150 of 189 [79.4%] triple-BAA positivity, P < 0.001). The 4-year diabetes risk was higher in single BAA(+) relatives with ZnT8A than ZnT8A(-) relatives (31 vs. 7%, P < 0.001). In multivariable analysis, age ≤ 20 years (hazard ratio 2.13, P = 0.03), IA-2A (2.15, P = 0.005), IAA (1.73, P = 0.01), ICA (2.37, P = 0.002), and ZnT8A (1.87, P = 0.03) independently predicted diabetes, whereas HLA type (high and moderate vs. low risk) and GAD65A did not (P = 0.81 and 0.86, respectively).

Conclusions: In relatives with one standard BAA, ZnT8A identified a subset at higher diabetes risk. ZnT8A predicted diabetes independently of ICA, the standard BAA, age, and HLA type. ZnT8A should be included in type 1 diabetes prediction and prevention studies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidences of diabetes in relatives positive for one standard BAA (IAA, GAD65A, or IA-2A) with or without ZnT8A. ICA+ relatives are excluded. The 95% confidence limits are indicated by the shaded areas. Diabetes risk was higher among ZnT8A+ relatives (P < 0.0001). mIAA, micro IAA; AB, antibody.
Figure 2
Figure 2
Cumulative incidences of diabetes in multiple autoantibody (at least two standard BAA) positive relatives with or without ZnT8A. ICA+ relatives are excluded. The 95% confidence limits are indicated by the shaded areas. Diabetes risk was higher among ZnT8A+ relatives (P = 0.0001).
Figure 3
Figure 3
The cumulative incidence of diabetes in relatives positive for two BAA (any two of GAD65A, IAA, IA-2A, and ZnT8A) with or without ICA. The 95% confidence limits are indicated by the shaded area. Diabetes risk was higher among ICA+ relatives (P < 0.0001). AB, antibody.

References

    1. Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 2010;95:25–33 - PubMed
    1. Diabetes Prevention Trial—Type 1 Diabetes Study Group Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685–1691 - PubMed
    1. Gale EA, Bingley PJ, Emmett CL, Collier TEuropean Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial ( ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925–931 - PubMed
    1. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial—Type 1. Diabetes Care 2005;28:1068–1076 - PubMed
    1. Skyler JS, Greenbaum CJ, Lachin JM, et al. ; Type 1 Diabetes TrialNet Study Group. Type 1 Diabetes TrialNet—an international collaborative clinical trials network. Ann N Y Acad Sci 2008;1150:14–24 - PMC - PubMed

Publication types

MeSH terms

Grants and funding